Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Exclusion Criteria

• •Current use of statin medication or statin use within 12 months of Screening visit.
• •Current systemic use of medications known to interact with statins and potentially increase toxicity, including (e.g., gemfibrozil, cyclosporine, clarithromycin, colchicine, niacin and fibrates).
• •History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to pravastatin (i.e., other statin medications)
• •Current use of any other investigational agents
• •Women who are pregnant. Women who are able to become pregnant must have a confirmed negative pregnancy test prior to enrollment.
• •Women who are breastfeeding. It is not known whether pravastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pravastatin, breastfeeding should be discontinued if the mother is treated with pravastatin.
• •Prior liver transplant
• •MELD score ≥30.
• •History of chronic myopathy
• •Active malignancy within the past 5 years (excluding HCC, basal/squamous cell skin cancer, or prostate cancer with a Gleason score 6 or less)
• •Known HIV infection
• •Hemophilia
• •Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data
• •Concurrent excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day)